AstraZeneca and Amgen's tezepelumab excels in unserved asthma subgroup
Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) and US biotech Amgen (Nasdaq: AMGN) looked set for major gains in Tuesday’s trading.
Markets generally are on an upswing but for these two, the rise might also be a lot to with the positive results from the NAVIGATOR Phase III trial for their potential new medicine tezepelumab in patients with severe, uncontrolled asthma.
"Tezepelumab has the potential to transform care for a broad population of severe asthma patients who are underserved today, including those without an eosinophilic phenotype"NAVIGATOR met the primary endpoint with tezepelumab added to standard of care (SoC) demonstrating a statistically-significant and clinically-meaningful reduction in the annualized asthma exacerbation rate over 52 weeks in the overall patient population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze